In the city of dreams, one family is trapped in a slow, waking nightmare. This isn’t a sudden story of loss; it’s a story of ...

John Maskill, 89, decided to walk the Cinder Track after losing his wife to Progressive Supranuclear Palsy (PSP) in March.

Amylyx is a high-risk biotech targeting rare diseases with strong cash reserves. Key trials soon may drive a 40% stock upside.